|
|
 |
|
|
|
 |
| Important endorsements |
| • |
The Advisory Committee on Immunization Practices (ACIP) to the Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend routine rotavirus vaccination for all eligible infants. |
| • |
According to the ACIP and AAP, infants in the United States should routinely receive a 3-dose series of rotavirus vaccine orally at 2, 4, and 6 months of age. |
| • |
To facilitate widespread rotavirus vaccination of all eligible children, the CDC has included RotaTeq in its Vaccines for Children program. |
| • |
Learn more about the ACIP recommendations. |
| • |
Learn more about the AAP recommendations. |
|
|
|
|
|
|
 |
| Make RotaTeq part of your practice today |
|
|
|
|
|
 |
| RotaTeq is fully liquid and ready to use. |
|
|
|
|
|
|
|
|
 |
| • |
RotaTeq is indicated for the prevention of rotavirus
gastroenteritis in infants and children caused by the serotypes G1, G2,
G3, and G4 when administered as a 3-dose series to infants between the ages
of 6 to 32 weeks. |
| • |
The first dose of RotaTeq should be administered
between 6 and 12 weeks of age. |
| • |
RotaTeq should not be administered to infants with
a demonstrated history of hypersensitivity to any component of the vaccine. |
| • |
No safety or efficacy data are available
for the administration of RotaTeq to infants who are potentially immunocompromised,
or with a history of gastrointestinal disorders. |
| • |
Caution is advised when considering whether
to administer RotaTeq to individuals with immunodeficient contacts. |
| • |
Over 71,000 infants were evaluated in
3 placebo-controlled clinical trials. Serious adverse events occurred in
2.4% of recipients of RotaTeq when compared to 2.6% of placebo recipients
within the 42-day period of a dose of RotaTeq. Hematochezia reported as
a serious adverse event for RotaTeq compared to placebo was <0.1% vs
<0.1%. The most frequently reported serious adverse events for RotaTeq
compared to placebo were bronchiolitis (0.6% vs 0.7%), gastroenteritis (0.2%
vs 0.3%), pneumonia (0.2% vs 0.2%), fever (0.1% vs 0.1%), and urinary tract
infection (0.1% vs 0.1%). |
| • |
In a subset of more than 11,000 infants in these trials,
the presence of adverse events was reported for 42 days after each dose.
Fever was observed at similar rates in vaccine and placebo recipients (42.6%
vs 42.8%). Adverse events that occurred at a statistically higher incidence
within 42 days of any dose among recipients of RotaTeq as compared with
placebo recipients were diarrhea (24.1% vs 21.3%), vomiting (15.2% vs 13.6%),
otitis media (14.5% vs 13.0%), nasopharyngitis (6.9% vs 5.8%), and bronchospasm
(1.1% vs 0.7%). |
| • |
In post-marketing experience, cases of intussusception
and Kawasaki disease have been reported in infants who have received RotaTeq. |
| • |
RotaTeq may not protect all vaccine recipients against
rotavirus. |
| • |
Before administering RotaTeq, please read the Prescribing
Information and Patient
Product Information. |
|
|
|
|
|
|
|
|
|
|
|
|
|
This site is intended only for healthcare professionals
of the United States, its territories, and Puerto Rico.
RotaTeq is a registered trademark of Merck & Co., Inc.
20753585(2)-01/08-RTQ
|
|
|
|
|
|
|
